1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Galectin Therapeutics Inc.

Galectin Therapeutics Inc.

GALT
Galectin Therapeutics Inc.US flagNASDAQ Capital Market
3.85
USD
-0.15
- -
253.22MMarket Cap
Galectin Therapeutics Inc.
GALT
(NASDAQ Capital Market)

Recent

price

3.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.7
-1.04
-0.7
-0.77
-0.77
-0.87
-0.76
-0.49
-0.38
-0.26
-0.41
-0.52
-0.65
-0.68
-0.76
-0.48
-0.41
Basic EPS, GAAP
-0.33
-0.47
-0.5
-0.44
-0.57
-0.7
-0.56
-0.45
-0.26
-0.21
-0.36
-0.42
-0.52
-0.55
-0.67
-0.37
-0.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-6.01
-5.77
-5.29
-6.04
-5.44
-5.81
-5.6
-5.1
-4.98
-4.14
-4.21
-4.62
-5.21
-5.89
-6.44
-6.77
-6.79
Book Value per Share
-0.25
-0.23
0.03
0.05
0.94
0.72
0.1
-0.22
-0.05
0.83
0.38
0.01
-0.58
-1.04
-1.69
-2.01
-2.05
Tangible Book Value per Share
9
12
15
17
22
24
29
36
39
52
57
59
59
60
62
64
64
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-6
-11
-10
-12
-16
-20
-21
-16
-14
-13
-23
-31
-39
-41
-47
-31
-26
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
4
4
8
8
28
25
12
1
7
45
24
33
8
12
-18
11
8
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
29
40
72
85
134
136
LT Debt
-2
4
8
8
28
25
12
1
7
46
24
3
-32
-60
-103
-126
-130
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
122
- -
- -
LT Borrowings
- -
134
136
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
2
2
Shares Outstanding
64
65
66
Market Capitalization
270
265
180

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13
19
16
Cash, Cash Equivalents & STI
12
18
14
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
136
8
7
Payables & Accruals
9
7
7
ST Debt
122
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-38.9%
-247.84%
22.44%
Free Cash Flow
8.98%
7.15%
-42.84%
Net Income, GAAP
8.37%
8.63%
-34.46%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
-24.83%
4.59%
-9.8%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.19
-0.2
-0.18
- -
-0.76
2025
-0.15
-0.12
-0.13
- -
-0.48
2026
-0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Odonate Therapeutics, Inc. (ODT)
Biocon Limited (BIOCON.BO)
ObsEva S.A. (OBSV)
Neurocrine Biosciences, Inc. (0K6R.L)
GenVec, Inc. (GNVC)
Wuhan YZY Biopharma Co Ltd (2496.HK)
Business
Galectin Therapeutics Inc. (NASDAQ: GALT) develops carbohydrate-based therapies targeting galectin proteins for the treatment of fibrosis and cancer. The company focuses on galectin-3, a protein implicated in inflammatory and fibrotic diseases, with its lead product candidate belapectin (GR-MD-02), a galectin-3 inhibitor administered intravenously in clinical development for non-alcoholic steatohepatitis (NASH) with cirrhosis and in combination therapies for hepatocellular carcinoma. Its pipeline also includes earlier-stage programs exploring galectin modulation for other fibrotic conditions and oncology indications.

Company News

APIChatGPT

  • seekingalpha.com

    Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside

  • zacks.com

    GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

  • globenewswire.com

    Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

  • globenewswire.com

    Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis

  • globenewswire.com

    Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

  • globenewswire.com

    Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology

  • globenewswire.com

    Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm

  • zacks.com

    Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

  • defenseworld.net

    Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)

  • defenseworld.net

    Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)

  • seekingalpha.com

    Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

  • newsfilecorp.com

    Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

  • newsfilecorp.com

    Securities Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Investors

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

  • globenewswire.com

    GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of - GALT